UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
__________________
Date of Report (Date of earliest event reported): March 23, 2016
___________________
COGENTIX MEDICAL, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-20970
|
13-3430173
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
5420 Feltl Road
Minnetonka, Minnesota
|
55343
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(952) 426-6140
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 23, 2016, Mr. Sven A. Wehrwein resigned from the Board of Directors and all committees of the Board of Directors including the Audit Committee Chair position. Mr. Wehrwein has served as a director, the Audit Committee Chair and audit committee financial expert of our company since our merger with Uroplasty, Inc. Prior to the merger, Mr. Wehrwein had served as a director of Uroplasty since August 2006. Mr. Wehrwein’s decision to resign did not involve any disagreement between Mr. Wehrwein, our company or our management on any matter relating to our operations, policies or practice.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: March 29, 2016
|
COGENTIX MEDICAL, INC.
|
||
|
By:
|
/s/ Robert C. Kill
|
||
|
Name:
|
Robert C. Kill
|
||
|
Title:
|
President, Chief Executive Officer
and Corporate Secretary
|
||
2